A literature review on the patients with autoimmune diseases following vaccination against infections

References

• Liang Y, Xu WD, Peng H, Pan HF, Ye DQ. SOCS signaling in autoimmune diseases: Molecular mechanisms and therapeutic implications. Eur J Immunol 2014; 44: 1265–75; PMID: 24595859; http://dx.doi.org/10.1002/eji.201344369
   PubMed Web of Science ®Google Scholar
• Liang Y, Pan HF, Ye DQ. Tc17 cells in immunity and systemic autoimmunity. Int Rev Immunol 2014; PMID: 25259411
   PubMed Web of Science ®Google Scholar
• Christen U, Hintermann E. Pathogen infection as a possible cause for autoimmunehepatitis. Int Rev Immunol 2014; 33: 296–313; PMID: 24911790; http://dx.doi.org/10.3109/08830185.2014.921162
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Urowitz MB Vaccination and auto-immune rheumatic diseases: Lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Curr Opin Rheumatol 2013; 25(2): 164–70; PMID: 23370371 http://dx.doi.org/10.1097/BOR.0b013e32835d2b7b
   PubMed Web of Science ®Google Scholar
• van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414–22; PMID: 21131643; http://dx.doi.org/10.1136/ard.2010.137216
   PubMed Web of Science ®Google Scholar
• Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, Fasth A, Minden K, Ravelli A, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011; 70: 1704–12; PMID: 21813547; http://dx.doi.org/10.1136/ard.2011.150193
   PubMed Web of Science ®Google Scholar
• Polkinghorne B, Ward K, Totaro R. Pandemic (H1N1) 2009 influenza. N S W Public Health Bull 2010; 21: 41–2; PMID: 21367344; http://dx.doi.org/10.1071/NB09031
   PubMedGoogle Scholar
• Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, Guillevin L, Villiger PM. Protective effect of A/H1N1 vaccination in immune-mediated disease: A prospectively controlled vaccination study. Rheumatol 2012; 51: 695–700; PMID: 22171015; http://dx.doi.org/10.1093/rheumatology/ker389
   PubMed Web of Science ®Google Scholar
• Aikawa NE, Campos LMA, Silva CA, Carvalho JF, Saad CG, Trudes G, Duarte A, Miraglia JL, Timenetsky Mdo C, et al. Glucocorticoid: Major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012; 39: 167–73; PMID: 22089462; http://dx.doi.org/10.3899/jrheum.110721
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29: 2555–7; PMID: 12465151
   PubMed Web of Science ®Google Scholar
• Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rhumatic Dis 2007; 66: 837–8; PMID: 17513572; http://dx.doi.org/10.1136/ard.2006.060285
   PubMed Web of Science ®Google Scholar
• Elkayam O, Paran D, Burke M, Zakut V, Ben-Yitshak R, Litinsky I, Caspi D. Pneumococcal vaccination of patients with systemic lupus erythematosus: Effects on generation of autoantibodies. Autoimmunity 2005; 38: 493–6; PMID: 16373254; http://dx.doi.org/10.1080/08916930500285725
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011; 63: 3723–32; PMID: 21834061; http://dx.doi.org/10.1002/art.30580
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol 2011; 30: 1555–61; PMID: 21956234; http://dx.doi.org/10.1007/s10067-011-1856-5
   PubMed Web of Science ®Google Scholar
• Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different anti-rheumatic drugs. Arthritis Res Ther 2013; 15: R1; PMID: 23286772; http://dx.doi.org/10.1186/ar4127
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control, Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children. MMWR Morb Mortal Wkly Rep 2010; 59: 258–61; PMID: 20224542
   PubMedGoogle Scholar
• Albrecht P, Antczak A, Hryniewicz W, Skoczyńska A, Radzikowski A, Kedziora-Kornatowska K, Bernatowska E, Stompór T, Grodzicki T, et al. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age]. Pol Merkur Lekarski 2014; 36(212): 79–87; PMID: 24720101
   PubMedGoogle Scholar
• Harper DM, Williams KB. Prophylactic HPV vaccines: Current knowledge of impact on gynecologic premalignancies. Discov Med Jul 2010; 10(50): 7–17; PMID: 20670593
   PubMedGoogle Scholar
• Harper DM, Vierthaler SL. Next generation cancer protection: The bivalent HPV vaccine for females. ISRN Obstet Gynecol 2011; 2011: 457204; PMID: 22111017; http://dx.doi.org/10.5402/2011/457204
   PubMedGoogle Scholar
• Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38: 295–301; PMID: 16206512; http://dx.doi.org/10.1080/08916930500144484
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Aron-Maor A. Vaccination andautoimmunity-‘vaccinosis’: a dangerous liaison? J Autoimmun 2000; 14(1): 1-10. PMID: 10648110. http://www.ncbi.nlm.nih.gov/pubmed/10648110
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clin Exp Rheumatol 2002; 20: 767–71; PMID: 12508767
   PubMedGoogle Scholar
• Soybilgic A, Onel KB, Utset T, Alexander K. Wagner–Weiner L. safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J 2013; 11: 29; PMID: 23924237; http://dx.doi.org/10.1186/1546-0096-11-29
   PubMed Web of Science ®Google Scholar
• Long HM, Taylor GS, Rickinson AB. Immune defence against EBV and EBV-associated disease. Curr Opin Immunol 2011; 23: 258–64; PMID: 21269819; http://dx.doi.org/10.1016/j.coi.2010.12.014
   PubMed Web of Science ®Google Scholar
• Lunemann JD, Tintore M, Messmer B, Strowig T, Rovira A, Perkal H, Caballero E, Münz C, Montalban X, Comabella M. Elevated Epstein–Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010; 67: 159–69; PMID: 20225269; http://dx.doi.org/10.1002/ana.21886
   PubMed Web of Science ®Google Scholar
• Dreyfus DH. Autoimmune disease: A role for new anti-viral therapies? Autoimmun Rev 2011; 11(2): 88–97; PMID: 21871974; http://dx.doi.org/10.1016/j.autrev.2011.08.005
   PubMed Web of Science ®Google Scholar
• Devlin M, Deodhar A, Davis M. Arthritis as a complication of intravesical BCG vaccine. BMJ 1994; 308: 1638; PMID: 8025443; http://dx.doi.org/10.1136/bmj.308.6944.1638
   PubMed Web of Science ®Google Scholar
• Dudelzak J, Curtis AR, Sheehan DJ, Lesher JL Jr. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guerin (BCG) immunotherapy. J Drugs Dermatol 2008; 7: 684; PMID: 18664162
   PubMed Web of Science ®Google Scholar
• Misery L, Combemale P. BCG-vaccine-induced lupus vulgaris and urticarial vasculitis. Dermatology 1993; 186: 274; PMID: 8513197; http://dx.doi.org/10.1159/000247372
   PubMed Web of Science ®Google Scholar
• Kass E, Straume S, Munthe E. Dermatomyositis after B.C.G. vaccination. Lancet 1978; 1: 772; PMID: 76775; http://dx.doi.org/10.1016/S0140-6736(78)90885-1
   PubMed Web of Science ®Google Scholar
• Farsinejad K, Daneshpazhooh M, Sairafi H, Barzegar M, Mortazavizadeh M. Lupus vulgaris at the site of BCG vaccination: Report of three cases. Clin Exp Dermatol 2009; 34: e167–9; PMID: 19094126; http://dx.doi.org/10.1111/j.1365-2230.2008.03041.x
   PubMedGoogle Scholar
• Wang H, Wu Q, Lin L, Cui P. Cutaneous tuberculosis: A diagnostic and therapeutic study of 20 cases. J Dermatolog Treat 2011; 22(6): 310–4; PMID: 20673149; http://dx.doi.org/10.3109/09546634.2010.487889
   PubMed Web of Science ®Google Scholar
• Gershon AA, Levin MJ, Weinberg A, Song LY, LaRussa PS, Steinberg SP, Bartlett P; Pediatric AIDS Clinical Trials Group 391 Team. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J 2009; 28: 653–5; PMID: 19561431; http://dx.doi.org/10.1097/INF.0b013e3181998f06
   PubMed Web of Science ®Google Scholar
• Gershon AA, Levin MJ, Weinberg A, Song LY, LaRussa PS, Steinberg SP, Bartlett P; Pediatric AIDS Clinical Trials Group 391 Team. Varicella Vaccine in Children and Adolescents with Systemic Lupus Erythematosus (SLE)-Immunogenicity and Safety; 2009. ACR-1521
   Google Scholar
• Pileggi GS, de Souza CBS, Ferriani VPL. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases using methotrexate and corticosteroids. Arthritis Rheum 2009; 60: 1091; PMID: 20235203
   PubMed Web of Science ®Google Scholar
• Nussinovitch M, Harel L, Varsano I. Arthritis after mumps and measles vaccination. Arch Dis Child 1995; 72: 348–9; PMID: 7763072; http://dx.doi.org/10.1136/adc.72.4.348
   PubMed Web of Science ®Google Scholar
• Tingle AJ, Allen M, Petty RE, Kettyls GD, Chantler JK. Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation. Ann Rheum Dis 1986; 45: 110–4; PMID: 3947141; http://dx.doi.org/10.1136/ard.45.2.110
   PubMed Web of Science ®Google Scholar
• Maillefert JF, Sibilia J, Toussirot E, Vignon E, Eschard JP, Lorcerie B, Juvin R, Parchin-Geneste N, Piroth C, Wendling D, et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology (Oxford) 1999; 38: 978–83; PMID: 10534549; http://dx.doi.org/10.1093/rheumatology/38.10.978
   PubMed Web of Science ®Google Scholar
• Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol 2004; 22(6): 749–55.
   PubMed Web of Science ®Google Scholar
• Crowe SR, Merrill JT, Vista ES, Dedeke AB, Thompson DM, Stewart S, Guthridge JM, Niewold TB, Franek BS, Air GM, et al. Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features. Arthritis Rheum 2011; 63: 2396–406; PMID: 21598235; http://dx.doi.org/10.1002/art.30388
   PubMed Web of Science ®Google Scholar
• Harper DM, Williams KB. Prophylactic HPV vaccines: Current knowledge of impact on gynecologic premalignancies. Discov Med Jul 2010; 10(50): 7–17; PMID: 20670593
   PubMedGoogle Scholar
• Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, Neville KL, Katz-Levy Y, Carrizosa A, Kim BS. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 1997; 3: 1133–6; PMID: 9334726; http://dx.doi.org/10.1038/nm1097-1133
   PubMed Web of Science ®Google Scholar
• Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006; 9: 80–94; http://dx.doi.org/10.1128/CMR.19.1.80-94.2006
   Web of Science ®Google Scholar
• McCoy L, Tsunoda I, Fujinami RS. Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 2006; 39: 9–19; PMID: 16455578; http://dx.doi.org/10.1080/08916930500484799
   PubMed Web of Science ®Google Scholar
• Kotzin BL, Leung J, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993; 54: 99–166; PMID: 8397479; http://dx.doi.org/10.1016/S0065-2776(08)60534-9
   PubMed Web of Science ®Google Scholar
• Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001; 108: 1097–104; PMID: 11602615; http://dx.doi.org/10.1172/JCI200114235
   PubMed Web of Science ®Google Scholar
• Ferri C, Zignego A. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol 2000; 12: 53–60; PMID: 10647955; http://dx.doi.org/10.1097/00002281-200001000-00009
   PubMed Web of Science ®Google Scholar
• Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, Grillet S, Seebach JD, Kaiser L, Wunderli W, et al. H1N1 Study Group: Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011; 63: 1486–96; PMID: 21384334; http://dx.doi.org/10.1002/art.30325
   PubMed Web of Science ®Google Scholar
• Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Huong DB, Wechsler B, Hervier B, Miyara M, Morel N, et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3502–11; PMID: 21811996; http://dx.doi.org/10.1002/art.30576
   PubMed Web of Science ®Google Scholar
• Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, Lommel P, Kaliskova E, Borys D, Schuerman L. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: Two open-label, randomised controlled trials. Lancet 2009; 374(9698): 1339–50; PMID: 19837254; http://dx.doi.org/10.1016/S0140-6736(09)61208-3
   PubMed Web of Science ®Google Scholar
• Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272–9; PMID: 17304653
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007; 46: 608–11; PMID: 17114801; http://dx.doi.org/10.1093/rheumatology/kel366
   PubMed Web of Science ®Google Scholar
• Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713–16; PMID: 17965123; http://dx.doi.org/10.1136/ard.2007.077552
   PubMed Web of Science ®Google Scholar
• Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podestà E, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNF alpha blockers: Safety and immunogenicity. Clin Immunol 2010; 134: 113–20; PMID: 19846344; http://dx.doi.org/10.1016/j.clim.2009.09.014
   PubMed Web of Science ®Google Scholar
• Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39: 442–7; PMID: 19246078; http://dx.doi.org/10.1016/j.semarthrit.2008.12.002
   PubMed Web of Science ®Google Scholar
• Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, Sugihara T, Nonomura Y, Hirose W, Nagasaka K, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 531–3; PMID: 18084712; http://dx.doi.org/10.3109/s10165-007-0632-5
   PubMedGoogle Scholar
• França IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, Laurindo IM, Precioso AR, Ishida MA, Sartori AM, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology 2012; 51: 2091–8; http://dx.doi.org/10.1093/rheumatology/kes202
   PubMed Web of Science ®Google Scholar
• Salinas GF, De Rycke L, Barendregt B, Paramarta JE, Hreggvidstdottir H, Cantaert T, van der Burg M, Tak PP, Baeten D. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis 2013; 72: 1037–43; PMID: 22968102; http://dx.doi.org/10.1136/annrheumdis-2011-201270
   PubMed Web of Science ®Google Scholar
• O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: A review of effectiveness and safety. Lupus 2006; 15: 778–83; PMID: 17153850; http://dx.doi.org/10.1177/0961203306069355
   PubMed Web of Science ®Google Scholar
• Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, Kroon FP. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine 2008; 26: 3528–33; PMID: 18502006; http://dx.doi.org/10.1016/j.vaccine.2008.04.028
   PubMed Web of Science ®Google Scholar
• Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007; 66: 1402–3; PMID: 17881666; http://dx.doi.org/10.1136/ard.2007.071878
   PubMed Web of Science ®Google Scholar
• van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62: 75–81; PMID: 20039396; http://dx.doi.org/10.1002/art.25033
   PubMed Web of Science ®Google Scholar
• Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2013; 33: 388–96; PMID: 23064976; http://dx.doi.org/10.1007/s10875-012-9813-x
   PubMed Web of Science ®Google Scholar
• Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis Rheum 2010; 62: 64–74; PMID: 20039397; http://dx.doi.org/10.1002/art.25034
   PubMed Web of Science ®Google Scholar
• Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012; 71: 2006–10; PMID: 22887851; http://dx.doi.org/10.1136/annrheumdis-2012-201950
   PubMed Web of Science ®Google Scholar
• Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, Hidaka T, Oishi K. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 2013; 72: 1362–6; PMID: 23345600; http://dx.doi.org/10.1136/annrheumdis-2012-202658
   PubMed Web of Science ®Google Scholar
• Tsuru T, Terao K, Murakami M, Matsutani T, Suzaki M, Amamoto T, Nakashima H, Akiyama A, Nishimoto N. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol 2014; 24: 511–6; PMID: 24252023; http://dx.doi.org/10.3109/14397595.2013.843743
   PubMed Web of Science ®Google Scholar
• Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, Bonfa E. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res 2013; 65: 476–80; PMID: 22949223; http://dx.doi.org/10.1002/acr.21838
   PubMed Web of Science ®Google Scholar
• Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 2013; 15: R171; PMID: 24286269; http://dx.doi.org/10.1186/ar4358
   PubMed Web of Science ®Google Scholar